TREATMENT OF ANEMIA IN HEMODIALYSIS-PATIENTS WITH ERYTHROPOIETIN - LONG-TERM EFFECTS ON EXERCISE CAPACITY

被引:0
|
作者
BARANY, P [1 ]
FREYSCHUSS, U [1 ]
PETTERSSON, E [1 ]
BERGSTROM, J [1 ]
机构
[1] HUDDINGE UNIV HOSP, DEPT CLIN PHYSIOL, S-14186 HUDDINGE, SWEDEN
关键词
ANEMIA; ERYTHROPOIETIN; EXERCISE; HEMODIALYSIS; UREMIA;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
1. The effects of correcting anaemia on exercise capacity were evaluated in 21 haemodialysis patients (aged 39 +/- 12 years) before starting treatment with recombinant human erythropoietin (Hb concentration, 73 +/- 10 g/l; total Hb, 59 +/- 12% of expected), after correction of the anaemia to a Hb concentration of 108 +/- 7 g/l and a total Hb 82 +/- 10% of expected, and in 13 of the patients after 12 months on maintenance recombinant human erythropoietin treatment (Hb concentration 104 +/- 14 g/l, total Hb 79 +/- 17% of expected). Fifteen healthy subjects (aged 41 +/- 9 years), who took no regular exercise, constituted the control group. Maximal exercise capacity was determined on a bicycle ergometer. Oxygen uptake, respiratory quotient, blood lactate concentration, heart rate and blood pressure were measured at rest and at maximal workload. 2. After 6 +/- 3 months on recombinant human erythropoietin, maximal exercise capacity increased from 108 +/- 27 W to 130 +/- 36 W (P<0.001) and the maximal oxygen uptake increased from 1.24 +/- 0.39 litres/min to 1.50 +/- 0.45 litres/min (P<0.001). No significant changes in respiratory quotient (1.16 +/- 0.13 versus 1.18 +/- 0.13) and blood lactate concentration (4.0 +/- 1.8 versus 3.6 +/- 1.1 mmol/1) at maximal workload were observed, but the blood lactate concentration in the patients was significantly lower than that in the control subjects (6.7 +/- 2.3 mmol/l, P<0.01). After the correction of anaemia, the aerobic power was still 38% lower in the patients than in the control subjects and 17% lower than the reference values. 3. After 12 months on maintenance recombinant human erythropoietin treatment (17 +/- 3 months from the start of the study), no further significant changes were observed in maximal exercise capacity (before start, 112 +/- 31 W, 6 +/- 3 months, 134 +/- 42 W, 17 +/- 3 months, 134 +/- 50 W), maximal oxygen uptake (before start, 1.33 +/- 0.45 litres/min; 6 +/- 3 months, 1.59 +/- 0.54 litres/min; 17 +/- 3 months, 1.75 +/- 0.78 litres/min) or blood lactate concentration (before start, 4.4 +/- 1.9 mmol/l; 6 +/- 3 months, 4.0 +/- 1.0 mmol/l; 17 +/- 3 months, 4.7 +/- 2.0 mmol/l). 4. Thus, in haemodialysis patients the improvement in maximal aerobic power after the correction of anaemia persists without marked changes during long-term treatment with recombinant human erythropoietin. We did not observe any effects on exercise capacity that could be attributed to a spontaneous increase in physical activity after treatment of anaemia.
引用
收藏
页码:441 / 447
页数:7
相关论文
共 50 条
  • [1] LONG-TERM EFFECTS ON QUALITY-OF-LIFE IN HEMODIALYSIS-PATIENTS OF CORRECTION OF ANEMIA WITH ERYTHROPOIETIN
    BARANY, P
    PETTERSSON, E
    KONARSKISVENSSON, JK
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1993, 8 (05) : 426 - 432
  • [2] RECOMBINANT ERYTHROPOIETIN IMPROVES EXERCISE CAPACITY IN ANEMIC HEMODIALYSIS-PATIENTS
    ROBERTSON, HT
    HALEY, NR
    GUTHRIE, M
    CARDENAS, D
    ESCHBACH, JW
    ADAMSON, JW
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1990, 15 (04) : 325 - 332
  • [3] EFFECTS OF ERYTHROPOIETIN TREATMENT ON THYROID-DYSFUNCTION IN HEMODIALYSIS-PATIENTS WITH RENAL ANEMIA
    TOMODA, F
    TAKADA, M
    IZUMINO, K
    OHHASHI, S
    UENO, H
    IIDA, H
    NEPHRON, 1994, 66 (03) : 307 - 311
  • [4] EXERCISE IN HEMODIALYSIS-PATIENTS AFTER TREATMENT WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    LUNDIN, AP
    AKERMAN, MJH
    CHESLER, RM
    DELANO, BG
    GOLDBERG, N
    STEIN, RA
    FRIEDMAN, EA
    NEPHRON, 1991, 58 (03) : 315 - 319
  • [5] LONG-TERM EFFECTS ON LYMPHOCYTOTOXIC ANTIBODIES AND IMMUNE REACTIVITY IN HEMODIALYSIS-PATIENTS TREATED WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    BARANY, P
    FEHRMAN, I
    GODOY, C
    CLINICAL NEPHROLOGY, 1992, 37 (02) : 90 - 96
  • [6] ATP PRODUCTION IN ISOLATED MUSCLE MITOCHONDRIA FROM HEMODIALYSIS-PATIENTS - EFFECTS OF CORRECTION OF ANEMIA WITH ERYTHROPOIETIN
    BARANY, P
    WIBOM, R
    HULTMAN, E
    BERGSTROM, J
    CLINICAL SCIENCE, 1991, 81 (05) : 645 - 653
  • [7] SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION OF ERYTHROPOIETIN IMPROVES ITS EFFICIENCY FOR THE TREATMENT OF ANEMIA IN HEMODIALYSIS-PATIENTS
    ALBITAR, S
    MEULDERS, Q
    HAMMOUD, H
    SOUTIF, C
    BOUVIER, J
    POLLINI, J
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 : 40 - 43
  • [8] The Association of Race With Erythropoietin Dose in Patients on Long-term Hemodialysis
    Lacson, Eduardo, Jr.
    Rogus, John
    Teng, Ming
    Lazarus, J. Michael
    Hakim, Raymond M.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 52 (06) : 1104 - 1114
  • [9] ERYTHROPOIETIN FOR ANEMIA IN HEMODIALYSIS-PATIENTS - RESULTS OF A MAINTENANCE STUDY (THE CANADIAN-ERYTHROPOIETIN-STUDY-GROUP)
    MUIRHEAD, N
    LAUPACIS, A
    WONG, C
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1992, 7 (08) : 811 - 816
  • [10] ERYTHROPOIETIN TREATMENT IN HEMODIALYSIS-PATIENTS WITH IRON OVERLOAD
    ELRESHAID, K
    JOHNY, KV
    HAKIM, A
    KAMEL, H
    SEBETA, A
    HOURANI, H
    KANYIKE, FB
    ACTA HAEMATOLOGICA, 1994, 91 (03) : 130 - 135